FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386784510> ?p ?o ?g. }

• W4386784510 endingPage "002" @default.
• W4386784510 startingPage "PO" @default.
• W4386784510 abstract "Abstract Introduction: In phase 2 studies (NCT02296684 and NCT02641093), neoadjuvant and adjuvant pembrolizumab demonstrated pathologic response and acceptable safety in high-risk, resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). KEYNOTE-689 (NCT03765918) is a randomized, open-label, phase 3 trial designed to evaluate neoadjuvant pembrolizumab and adjuvant pembrolizumab plus standard of care (SOC) in previously untreated LA HNSCC. Materials and Methods: Eligible patients have histologically confirmed, newly diagnosed, resectable, LA HNSCC (stage III oropharyngeal p16-positive disease [T4 (N0-N2), M0]; stage III/IVA oropharyngeal p16-negative; or stage III/IVA laryngeal or hypopharyngeal disease or disease of the oral cavity, independent of p16 status), evaluable disease, newly obtained core or excisional biopsy, and ECOG performance status of 0 or 1. Approximately 704 patients will be randomly assigned 1:1 to arm A: neoadjuvant pembrolizumab 200 mg every 3 weeks (2 cycles), surgical resection, then adjuvant pembrolizumab 200 mg every 3 weeks (15 cycles) plus SOC or arm B: surgical resection then adjuvant SOC. SOC is adjuvant radiotherapy, 60 Gy total, 30 fractions for low-risk disease; adjuvant chemoradiation, 3 cycles of cisplatin 100 mg/m2 every 3 weeks plus 66 Gy total, 33 fractions for high-risk disease; adjuvant radiation, 70 Gy total, 35 fractions for gross residual disease. Randomization will be stratified by primary tumor site (oropharynx/oral cavity vs larynx vs hypopharynx), tumor stage (III vs IVA), and PD-L1 status (TPS ≥50% vs TPS &lt;50%). Postoperative imaging will occur 12 weeks after completion of SOC treatment, every 3 months until year 3, then every 6 months until year 5. Dual primary end points are major pathologic response and event-free survival per RECIST v1.1. Secondary end points are overall survival, pathologic complete response, health-related quality-of-life, and safety. End points except safety will be evaluated in patients whose tumors express PD-L1 CPS ≥1 and regardless of PD-L1 status. Results: Recruitment is ongoing at sites in Asia, Australia, Europe, North America, and South America. Conclusions: Results of KEYNOTE-689 will elucidate the role of pembrolizumab as neoadjuvant therapy and adjuvant therapy plus SOC in patients with LA HNSCC. Citation Format: Arkadiy Klochikhin, Robert I. Haddad, Amichay Meirovitz, Sufia Safina, Irene Brana, Christophe Le Tourneau, Ravindra Uppaluri, Nancy Y. Lee, Ezra E. W. Cohen, Rebecca Chernock, William Westra, Hong Liu, Burak Gumuscu, Kimberly Benjamin, Douglas Adkins. Pembrolizumab as neoadjuvant and adjuvant therapy in combination with standard of care in resectable, locally advanced head and neck squamous cell carcinoma: Phase 3 KEYNOTE-689 [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-002." @default.
• W4386784510 created "2023-09-16" @default.
• W4386784510 creator A5001334189 @default.
• W4386784510 creator A5006729078 @default.
• W4386784510 creator A5016059034 @default.
• W4386784510 creator A5016521611 @default.
• W4386784510 creator A5018145418 @default.
• W4386784510 creator A5021281217 @default.
• W4386784510 creator A5052610122 @default.
• W4386784510 creator A5057287134 @default.
• W4386784510 creator A5059172426 @default.
• W4386784510 creator A5063649167 @default.
• W4386784510 creator A5064319129 @default.
• W4386784510 creator A5066002385 @default.
• W4386784510 creator A5072952712 @default.
• W4386784510 creator A5079422406 @default.
• W4386784510 creator A5080875822 @default.
• W4386784510 date "2023-09-15" @default.
• W4386784510 modified "2023-09-30" @default.
• W4386784510 title "Abstract PO-002: Pembrolizumab as neoadjuvant and adjuvant therapy in combination with standard of care in resectable, locally advanced head and neck squamous cell carcinoma: Phase 3 KEYNOTE-689" @default.
• W4386784510 doi "https://doi.org/10.1158/1557-3265.aacrahns23-po-002" @default.
• W4386784510 hasPublicationYear "2023" @default.
• W4386784510 type Work @default.
• W4386784510 citedByCount "0" @default.
• W4386784510 crossrefType "journal-article" @default.
• W4386784510 hasAuthorship W4386784510A5001334189 @default.
• W4386784510 hasAuthorship W4386784510A5006729078 @default.
• W4386784510 hasAuthorship W4386784510A5016059034 @default.
• W4386784510 hasAuthorship W4386784510A5016521611 @default.
• W4386784510 hasAuthorship W4386784510A5018145418 @default.
• W4386784510 hasAuthorship W4386784510A5021281217 @default.
• W4386784510 hasAuthorship W4386784510A5052610122 @default.
• W4386784510 hasAuthorship W4386784510A5057287134 @default.
• W4386784510 hasAuthorship W4386784510A5059172426 @default.
• W4386784510 hasAuthorship W4386784510A5063649167 @default.
• W4386784510 hasAuthorship W4386784510A5064319129 @default.
• W4386784510 hasAuthorship W4386784510A5066002385 @default.
• W4386784510 hasAuthorship W4386784510A5072952712 @default.
• W4386784510 hasAuthorship W4386784510A5079422406 @default.
• W4386784510 hasAuthorship W4386784510A5080875822 @default.
• W4386784510 hasConcept C121608353 @default.
• W4386784510 hasConcept C126322002 @default.
• W4386784510 hasConcept C141071460 @default.
• W4386784510 hasConcept C143998085 @default.
• W4386784510 hasConcept C146357865 @default.
• W4386784510 hasConcept C151730666 @default.
• W4386784510 hasConcept C2776530083 @default.
• W4386784510 hasConcept C2776833033 @default.
• W4386784510 hasConcept C2777701055 @default.
• W4386784510 hasConcept C2777863537 @default.
• W4386784510 hasConcept C2777982462 @default.
• W4386784510 hasConcept C2778292576 @default.
• W4386784510 hasConcept C2780057760 @default.
• W4386784510 hasConcept C2780474809 @default.
• W4386784510 hasConcept C509974204 @default.
• W4386784510 hasConcept C530470458 @default.
• W4386784510 hasConcept C71924100 @default.
• W4386784510 hasConcept C86803240 @default.
• W4386784510 hasConceptScore W4386784510C121608353 @default.
• W4386784510 hasConceptScore W4386784510C126322002 @default.
• W4386784510 hasConceptScore W4386784510C141071460 @default.
• W4386784510 hasConceptScore W4386784510C143998085 @default.
• W4386784510 hasConceptScore W4386784510C146357865 @default.
• W4386784510 hasConceptScore W4386784510C151730666 @default.
• W4386784510 hasConceptScore W4386784510C2776530083 @default.
• W4386784510 hasConceptScore W4386784510C2776833033 @default.
• W4386784510 hasConceptScore W4386784510C2777701055 @default.
• W4386784510 hasConceptScore W4386784510C2777863537 @default.
• W4386784510 hasConceptScore W4386784510C2777982462 @default.
• W4386784510 hasConceptScore W4386784510C2778292576 @default.
• W4386784510 hasConceptScore W4386784510C2780057760 @default.
• W4386784510 hasConceptScore W4386784510C2780474809 @default.
• W4386784510 hasConceptScore W4386784510C509974204 @default.
• W4386784510 hasConceptScore W4386784510C530470458 @default.
• W4386784510 hasConceptScore W4386784510C71924100 @default.
• W4386784510 hasConceptScore W4386784510C86803240 @default.
• W4386784510 hasIssue "18_Supplement" @default.
• W4386784510 hasLocation W43867845101 @default.
• W4386784510 hasOpenAccess W4386784510 @default.
• W4386784510 hasPrimaryLocation W43867845101 @default.
• W4386784510 hasRelatedWork W2096393323 @default.
• W4386784510 hasRelatedWork W2146329765 @default.
• W4386784510 hasRelatedWork W2408170775 @default.
• W4386784510 hasRelatedWork W2415467068 @default.
• W4386784510 hasRelatedWork W2462717890 @default.
• W4386784510 hasRelatedWork W3210496311 @default.
• W4386784510 hasRelatedWork W4292255383 @default.
• W4386784510 hasRelatedWork W4323657820 @default.
• W4386784510 hasRelatedWork W4366439393 @default.
• W4386784510 hasRelatedWork W4377238167 @default.
• W4386784510 hasVolume "29" @default.
• W4386784510 isParatext "false" @default.
• W4386784510 isRetracted "false" @default.
• W4386784510 workType "article" @default.